MUHC Vaccine Study Centre

The MUHC Vaccine Study Centre (VSC) conducts vaccine and epidemiological research. Located in Pierrefonds, Quebec, the VSC has conducted over 200 studies with over 8,000 participants enrolled to date.

About the MUHC Vaccine Study Centre

Founded in 1991, the MUHC Vaccine Study Centre (VSC) is affiliated with the McGill University Health Centre (MUHC) and the Research Institute of the MUHC (RI-MUHC). The experienced personnel at the VSC conduct vaccine and epidemiological research in collaboration with participants and sponsors. The VSC staff are physicians, nurses and highly trained research personnel, experienced in clinical research and meticulous in their work. They provide a caring, respectful and bilingual environment for study participants.

Our team

Leadership
Title
Michael Libman, MD
Co-director
Deirdre McCormack, B.Sc.(N) RN
Clinical research manager
Investigators
Affiliation
Michael Libman, MD
McGill University Health Centre
Jesse Papenburg, MD M.Sc.
Montreal Children’s Hospital (MUHC)
Earl Rubin, MD
Montreal Children’s Hospital (MUHC)
Inés Colmegna, MD
McGill University Health Centre
Staff
Title
Monica Makarewicz, RN
Nurse coordinator
Janice Couture, RN
Nurse coordinator
Giuliana Alfonso, RN
Nurse coordinator
Patricia Brown, RN
Nurse coordinator
Diane Delli Colli, B.Sc.(N), RN
Nurse coordinator
Jill Gale, BSc(N), M.Sc.(N), RN
Nurse coordinator
Sandra Safulko, B.Sc.(N), RN
Research nurse
Carina Mazloumian, B.Sc.(N), RN
Research nurse
Sylvie Nicholson, RN
Research nurse
Cathy Clarke
Research assistant
Alice Weir
Research assistant
Allison Couture, B.Ed.
Research assistant
Mila Gonzales, M.Sc.
Research assistant
Joanne Richardson
Research assistant
Sazini Nzula, PhD
Research assistant

Ongoing clinical studies, active recruitment

ADULT STUDIES

Study Name
Study Details
COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD)
Sponsor: CIHR
Phase: 2/3
Target population: Adults with a systemic autoimmune rheumatic disease
Status: Recruiting
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
Sponsor: Moderna
Phase: 3
Target population: Women aged 16 to 40 years
Status: Not yet recruiting
A Lyme disease vaccine (VLA15) for the prevention of Lyme disease caused by Borrelia species in individuals ≥5 years of age.
Sponsor: Pfizer
Phase: 3
Target population: Healthy adults ≥ 18 years of age
Status: Not yet recruiting

PEDIATRIC STUDIES

Study Name
Study Details
Efficacy and Safety of MK-1654 in Infants (MK-1654-004)
Sponsor: Merck
Phase: 2/3
Target population: Infants
Status: Recruiting
A Lyme disease vaccine (VLA15) for the prevention of Lyme disease caused by Borrelia species in individuals ≥5 years of age.
Sponsor: Pfizer
Phase: 3
Target population: Healthy children ≥ 5 years of age
Status: Not yet recruiting

Interested in more information about our studies? Please contact us.

Ongoing clinical studies, closed to recruitment

Study Name
Study Details
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
Sponsor: Medicago
Phase: 2/3
Target population: Adults 18 years and older
Status: Closed to recruitment. Long-term follow-up.
RECOVER: REinfection in COVID-19 Estimation of Risk: extension
Sponsor: CIHR
Target population: Health Care Workers who have had COVID-19
Status: Closed to recruitment. Long-term follow-up.
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases (COVIAAD)
Sponsor: RI-MUHC
Phase: 3
Target population: Adults with rheumatic diseases
Status: Closed to recruitment. Long-term follow-up.
A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
Sponsor: Moderna
Phase: 3
Target population: Healthy children aged 6 months to < 12 years
Status: Closed to recruitment. Long-term follow-up.
20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
Sponsor: Pfizer
Phase: 3
Target population: Healthy infants
Status: Closed to recruitment. Long-term follow-up.

Interested in more information about our studies? Please contact us.

News

April 2022: 6,7 millions de dollars pour étudier les impacts de la COVID-19 sur les enfants (nouvelles CUSM mentionnant Dr Jesse Papenburg)

March 2022: WHO rejects Quebec's Medicago vaccine over tobacco ties (CTV, featuring Dr. Michael Libman)

January 2022: Omicron and vaccines: Experts break down the science behind COVID-19 jabs (Global news, featuring Dr Jesse Papenburg)

December 2021: Montreal sees high COVID-19 infections among young kids as admissions increase at Children's Hospital (CTV, featuring Dr Earl Rubin)

December 2021: Worried the children’s vaccine was developed too quickly? Nervous about long-term side effects? (Science Up First website, Interview featuring Dr Jesse Papenburg)

October 2021: Vaccinating children will be key for kids and society at large, experts say (CTV, featuring Dr Jesse Papenburg)

Contact the MUHC Vaccine Study Centre

For more information about the MUHC Vaccine Study Centre and to learn more about participating in studies at the VSC:

Phone: 514-624-7855

Email: coordinators.vsc [at] muhc.mcgill.ca

Visit: 14770 Pierrefonds Blvd., unit 204, Pierrefonds, Quebec H9H 4Y6

Useful links

The MUHC Vaccine Study Centre is proud to collaborate with other vaccine research centres and networks across Canada.